6086
M.-Y. Jang et al. / Tetrahedron Letters 54 (2013) 6084–6086
1
15.
a-(Uridin-1-yl)-2’,3’-O-dibenzoyl-L-threose (CCDC 183997) was downloaded
Scheme 1. Proposed mechanism of synthesis of compound 10.
19. General procedure of mono-2’-O-debenzoylation of 2’,3’-dibenzoyl threose
nucleosides: to a solution of 10a-(thymin-1-yl)-2’,3’-di-O-benzoyl-
L-threose 7b
(1.0 g, 2.35 mmol) in dry THF (100 ml) was added fresh prepared 0.1 M KOtBu
in THF (58.6 ml, 5.86 mmol). After stirring for 5 min, the mixture was
quenched by addition of 1 N HCl (5.86 ml, 5.86 mmol). After removing
volatiles, the residue was dissolved with DCM and washed with water, brine,
dried over Na2SO4 and evaporated under reduced pressure. The crude residue
was purified by silica gel chromatography (CH2Cl2/MeOH 30/1) to afford 10a
-
Scheme 2. Selective deprotection of O6-diphenylcarbamoyl group of compound 7d.
(thymin-1-yl)-30-O-benzoyl-
L
-threose (0.71 g, 91%) as white foam.
1
0a-(N6-Benzoyladenin-9-yl)-30-O-benzoyl-
L
-threose (8a): 1H NMR (300 MHz,
confirmed by HMBC and mass analysis. An attempt to obtain only
one product (compound 10) in the reaction mixture by adding
more potassium tert-butoxide was not successful. Even with
10 equiv of potassium tert-butoxide, a considerable amount of
starting material remained and a complex mixture of products
was obtained. To avoid this side reaction, the diphenylcarbamoyl
group of 7d was selectively removed by a treatment with glacial
acetic acid18 (Scheme 2). Compound 7e could be successfully mono
20-O-debenzoylated with 4.5 equivalents of potassium tert-butox-
ide (Table 1).
Purine threose nucleosides showed lower yield compared to
pyrimidine threose nucleosides as a certain amount of starting
material (ꢁ10%) remained. Adding more base or longer reaction
time did not improve the yield because it caused 30-O-
debenzoylation.
CDCl3): d 9.44 (br s, 1H, NH), 8.65 (s, 1H, H8), 8.34 (s, 1H, H2), 7.99 (d,
J = 7.2 Hz, 2H, Bz), 7.70 (d, J = 7.1 Hz, 2H, Bz), 7.55 (t, J = 7.4 Hz, 1H, Bz), 7.45 (t,
J = 7.6 Hz, 3H, Bz), 7.32 (t, J = 7.8 Hz, 2H, Bz), 6.23 (d, J = 1.7 Hz, 1H, H10), 5.48–
5.49 (m, 1H, H3’), 5.03 (s, 1H, H20), 4.59 (dd, J = 4.5, 10.8 Hz, 1H, H4’), 4.47(dd,
J = 1.4, 10.6 Hz, 1H, H40) ppm. 13C NMR (75 MHz, DMSO): d 165.56, 164.93,
151.76, 151.57, 150.31, 142.41, 133.53, 133.39, 132.38, 129.17, 128.89, 128.69,
128.47, 128.42, 125.88, 90.47, 78.25, 77.21, 72.59 ppm. HRMS (ESI+) calcd for
C
23H20N5O5 [M+H]+ 446.1459, found 446.1460.
0a-(Thymin-1-yl)-30-O-benzoyl- -threose (8b): 1H NMR (300 MHz, CDCl3): d
1
L
10.30 (br s, 1H, NH), 7.83 (d, J = 7.1 Hz, 2H, Bz), 7.58 (t, J = 7.4 Hz, 1H, Bz), 7.44
(s, 1H, H6), 7.41 (t, J = 7.5 Hz, 2H, Bz), 5.87 (s, 1H, H10), 5.45 (d, J = 3.4 Hz, 1H,
H3’), 4.60 (dd, J = 3.6, 11.1 Hz, 1H, H40), 4.58 (s, 1H, H20), 4.46 (d, J = 10.8 Hz, 1H,
H40), 1.84 (d, J = 0.9 Hz, 3H, CH3) ppm. 13C NMR (75 MHz, CDCl3): d 165.21,
164.77, 151.01, 135.89, 133.94, 129.61, 128.98, 128.78, 110.27, 93.98, 79.38,
77.63, 75.10 ppm. HRMS (ESI+) calcd for C16H17N2O6 [M+H]+ 333.1081, found
333.1077.
1
0a-(N4-Benzoylcytosin-1-yl)-30-O-benzoyl- -threose (8c): 1H NMR (300 MHz,
L
CDCl3): d 8.09 (d, J = 7.5 Hz, 1H, H6), 7.95 (d, J = 7.2 Hz, 2H, Bz), 7.72 (d,
J = 7.2 Hz, 2H, Bz), 7.61 (d, J = 7.5 Hz, 1H, H5), 7.57 (t, J = 7.3 Hz, 1H, Bz), 7.43–
7.50 (m, 3H, Bz), 7.30 (t, J = 7.8 Hz, 2H, Bz), 6.00 (s, 1H, H10), 5.55 (d, J = 3.3 Hz,
1H, H30), 4.72 (s, 1H, H20), 4.66 (dd, J = 3.7, 10.9 Hz, 1H, H40), 4.46 (d, J = 10.8 Hz,
1H, H40) ppm. 13C NMR (75 MHz, CDCl3): d 166.85, 165.31, 162.89, 155.94,
144.40, 133.63, 133.13, 133.10, 129.65, 128.93, 128.89, 128.49, 127.94, 94.60,
94.88, 79.18, 78.09, 74.95 ppm. HRMS (ESI+) calcd for C22H20N3O6 [M+H]+
422.1347, found 422.1351.
In summary, we have developed a simple and efficient regiose-
lective 20-O-debenzoylation method of 2’,3’-di-O-benzoyl threose
nucleosides.19 The resulting products are valuable intermediates
for the synthesis of new 20-modified threose nucleosides.
1
0a-(N2-Acetylguanin-9-yl)-30-O-benzoyl- -threose (8e): 1H NMR (300 MHz,
L
MeOD): d 8.11 (s, 1H, H8), 7.66 (d, J = 8.5 Hz, 2H, Bz), 7.55 (t, J = 7.44 Hz, 1H,
Bz), 7.38 (t, J = 7.8 Hz, 2H, Bz), 5.99 (d, J = 0.72 Hz, 1H, H10), 5.39–5.54 (m, 1H,
H30), 4.93 (s, 1H, H20), 4.57 (dd, J = 4.5, 10.8 Hz, 1H, H40), 4.48 (dd, J = 1.1,
10.7 Hz, 1H, H40), 2.18 (s, 3H, CH3) ppm. 13C NMR (75 MHz, MeOD): d 174.85,
166.70, 157.29, 149.70, 149.32, 139.09, 134.63, 130.36, 130.27, 129.62, 92.77,
79.70, 79.34, 74.52, 23.84 ppm. HRMS (ESI+) calcd for C18H18N5O6 [M+H]+
400.1251, found 400.1248.
References and notes
1
0a-(N2-Acetylguanin-9-yl)-30-O-benzoyl-20-O-diphenylcarbamoyl-L-threose
(10): 1H NMR (300 MHz, CDCl3): d 11.93 (s, 1H, NH), 9.89 (s, 1H, NH), 7.95 (s,
1H, H8), 7.66 (d, J = 7.2 Hz, 2H, Bz), 7.52 (t, J = 7.4 Hz, 1H, Bz), 7.21–7.36 (m,
12H, Bz, Ph), 6.15 (s, 1H, H20), 5.99 (s, 1H, H10), 5.43 (br s, 1H, H30), 4.30 (dd,
J = 1.8, 10.8 Hz, 1H, H40), 4.21 (dd, J = 4.8, 10.8 Hz, 1H, H40) ppm. 13C NMR
(75 MHz, CDCl3): d 172.38, 165.43, 155.63, 152.99, 147.91, 147.65, 141.74,
137.29, 134.09, 129.47, 128.76, 128.37, 126.99, 121.72, 89.01, 79.89, 75.79,
73.50, 24.26 ppm. HRMS (ESI+) calcd for C31H27N6O7 [M+H]+ 595.1936, found
595.1938.